"Junshi Biosciences' phase III clinical study (NEOTORCH) for toripalimab in resectable stage II-III NSCLC met primary endpoints. The company plans to submit a supplemental new drug application (sNDA) to expand approval. Toripalimab combined with chemotherapy significantly improved event-free survival (EFS)."